Oncternal Therapeutics Announces Presentation of Interim Phase 1/2 Data Update for Cirmtuzumab in Combination with Ibrutinib at ASH 2020 Virtual Annual Meeting

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment